Zobrazeno 1 - 10
of 966
pro vyhledávání: '"Carl H. June"'
Autor:
Ugur Uslu, Lijun Sun, Sofia Castelli, Amanda V. Finck, Charles-Antoine Assenmacher, Regina M. Young, Zhijian J. Chen, Carl H. June
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART) directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a newly developed stimulator of interferon genes (STING) agon
Externí odkaz:
https://doaj.org/article/0776d7dc8ea14173bb63673e70265732
Autor:
Abdulla Berjis, Deeksha Muthumani, Oscar A. Aguilar, Oz Pomp, Omar Johnson, Amanda V. Finck, Nils W. Engel, Linhui Chen, Nicolas Plachta, John Scholler, Lewis L. Lanier, Carl H. June, Neil C. Sheppard
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Human natural killer (NK) cell-based therapies are under assessment for treating various cancers, but cryopreservation reduces both the recovery and function of NK cells, thereby limiting their therapeutic feasibility. Using cryopreservation
Externí odkaz:
https://doaj.org/article/3fd910c3f98f4e43883f2a9ab9531d8c
Autor:
David Mai, Tifara Boyce, Aakash Mehta, Jordan Reff, John Scholler, Neil C. Sheppard, Carl H. June
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Loss of inflammatory effector function, such as cytokine production and proliferation, is a fundamental driver of failure in T cell therapies against solid tumors. Here, we used CRISPR/Cas9 to genetically disrupt ZFP36, an RNA binding protei
Externí odkaz:
https://doaj.org/article/43e2928bff434cb489ee369a6bdcb722
Autor:
Julie K. Jadlowsky, Rachel Leskowitz, Stephen McKenna, Jayashree Karar, Yujie Ma, Anlan Dai, Gabriela Plesa, Fang Chen, Kathleen Alexander, Jennifer Petrella, Nan Gong, Wei-Ting Hwang, Olivia Farrelly, Julie Barber-Rotenberg, Shannon Christensen, Vanessa E. Gonzalez, Anne Chew, Joseph A. Fraietta, Carl H. June
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 1, Pp 101186- (2024)
The use of lentiviral vectors in cell and gene therapy is steadily increasing, both in commercial and investigational therapies. Although existing data increasingly support the usefulness and safety of clinical-grade lentiviral vectors used in cell m
Externí odkaz:
https://doaj.org/article/7bc0c17d5d0e4617bc7ee7d437b08ef4
Autor:
Zebin Xiao, Leslie Todd, Li Huang, Estela Noguera-Ortega, Zhen Lu, Lili Huang, Meghan Kopp, Yue Li, Nimisha Pattada, Wenqun Zhong, Wei Guo, John Scholler, Maria Liousia, Charles-Antoine Assenmacher, Carl H. June, Steven M. Albelda, Ellen Puré
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract The desmoplastic stroma in solid tumors presents a formidable challenge to immunotherapies that rely on endogenous or adoptively transferred T cells, however, the mechanisms are poorly understood. To define mechanisms involved, here we treat
Externí odkaz:
https://doaj.org/article/8293ae22274440439fe76629503609b5
Autor:
Emily A. Blumberg, Julia Han Noll, Pablo Tebas, Joseph A. Fraietta, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Rene Martins, Briana M. Hudson, Kalyan Chavda, Christina M. Bailey, Sarah E. Church, Hooman Noorchashm, Wei-Ting Hwang, Carl H. June, Elizabeth O. Hexner
Publikováno v:
JCI Insight, Vol 7, Iss 11 (2022)
BACKGROUND COVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine sto
Externí odkaz:
https://doaj.org/article/6597f6dab218404fa9ecd0f6232979e4
Autor:
Saba Ghassemi, Francisco J. Martinez-Becerra, Alyssa M. Master, Sarah A. Richman, David Heo, John Leferovich, Yitao Tu, Juan Carlos García-Cañaveras, Asma Ayari, Yinan Lu, Ai Wang, Joshua D. Rabinowitz, Michael C. Milone, Carl H. June, Roddy S. O’Connor
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 595-606 (2020)
Effective chimeric antigen receptor (CAR)-T cell therapy is dependent on optimal cell culture methods conducive to the activation and expansion of T cells ex vivo, as well as infection with CAR. Media formulations used in CAR-T cell manufacturing hav
Externí odkaz:
https://doaj.org/article/3c8878a6387c4c229e27c84bfdffb1ba
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-4 (2020)
As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the
Externí odkaz:
https://doaj.org/article/b79c612e2f44404b8f5683d98f5ab4b9
Autor:
Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, Asen Bagashev, Derek A. Oldridge, Jaclyn Rosenthal, John Van Arnam, Jos J. Melenhorst, Diwakar Mohan, Amanda M. DiNofia, Minjie Luo, Sindhu Cherian, Jonathan R. Fromm, Gerald Wertheim, Andrei Thomas-Tikhonenko, Michele Paessler, Carl H. June, Eline T. Luning Prak, Vijay G. Bhoj, Stephan A. Grupp, Shannon L. Maude, Susan R. Rheingold
Publikováno v:
Blood Advances, Vol 3, Iss 22, Pp 3539-3549 (2019)
Abstract: Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level,
Externí odkaz:
https://doaj.org/article/e70ab1bdc076485da3ba01a3a1e59b84
Autor:
Archana Thakur, John Scholler, Ewa Kubicka, Edwin T. Bliemeister, Dana L. Schalk, Carl H. June, Lawrence G. Lum
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming wit
Externí odkaz:
https://doaj.org/article/44fc3950d1424b9fb6857b674cd72b67